Abeona Therapeutics

CEO Vishwas Seshadri brings relevant autologous cell/gene therapy launch experience (e.g., Breyanzi at Celgene/BMS) and has led Abeona since 2021 through regulatory remediation and approval.

The board adds seasoned operators across gene therapy, development and finance. 2025 execution included resolving an FDA release‑assay issue, activating multiple QTCs, securing a permanent J‑code and expanding access.

Near‑term tests are operational: sustaining quality, compressing referral‑to‑treatment timelines, and scaling to the stated mid‑2026 capacity.